Purpose: Reliable biomarkers that predict prostate cancer outcomes are urgently needed to improve and personalize treatment approaches. With this goal in mind, we individually and collectively appraised common genetic polymorphisms related to estradiol metabolic pathways to find prostate cancer prognostic markers.
Introduction
Prostate cancer is the most common cancer in men and the second leading cause of cancer death in North America (1) . A clinically relevant, prognostic molecular signature defining aggressive and indolent prostate cancer is eagerly awaited to personalize treatment approaches. Indeed, prostate cancer is a complex genetic disease, and its clinical heterogeneity underscores the need to identify biomarkers for prognostication purposes at all stages of prostate cancer.
Simple, noninvasive, and reliable molecular markers are necessary to identify men at high risk for prostate cancer progression. Such prognostic markers for use in localized, locally advanced, and metastatic settings would considerably improve prostate cancer management.
Recently, circulating tumor cells and whole-blood geneexpression signatures were elegantly shown to be potential biomarkers of cancer progression, and use of these markers enabled identification of several differentially regulated genes in immune or androgen signaling that may be useful for predicting outcomes for patients with castration-resistant prostate cancer (2, 3) . Another useful and much simpler approach to predict prostate cancer outcomes relies on identifying key inherited genetic variations involved in disease progression (4, 5) . In fact, potential molecular determinants of clinical outcomes have been identified as components encoded by immune system genes (6, 7), sex steroid-related genes (4, 8) , and, with conflicting results, prostate cancer risk alleles (9) (10) (11) (12) . The importance of studying host steroidogenic pathways comes from observations that prostate cells possess the enzymatic machinery for intracrine conversion of precursors into more potent Authors' Affiliations:
1 Pharmacogenomics Laboratory, Centre Hospitalier Universitaire de Qu ebec (CHU de Qu ebec) Research Center and Faculty of Pharmacy; and hormones (13, 14) and that these pathways are dysregulated in prostate cancer (15) . Moreover, the consequence of sustained and active steroidogenesis in cancer cells is highlighted by the observation that castration-resistant prostate cancer can still be driven by sex steroid hormones despite a low circulating testosterone (T) level (14) . Several germline polymorphisms in sex steroid metabolic pathways have been shown to be associated with localized and advanced prostate cancer outcomes related to a meaningful influence of inherited genetic variations in the androgenic pathway on progression (4, 8) . Therefore, in addition to tumor markers, circulating tumor cells, and whole-blood gene-expression profiles (2, 3, 16) , host polymorphisms might assist in predicting tumor behavior and serve as a simple and reliable assay easily analyzed from germline DNA of any human.
Because we know that steroidogenic pathways are important to prostate cancer progression, we focused on identifying genetic polymorphisms related to sex steroid metabolic genes associated with endogenous hormone levels and prostate cancer progression with an emphasis on the biotransformation pathways involving estradiol and its metabolites. Previous important studies have suggested that estrogen affects prostate carcinogenesis (17) (18) (19) . In rodents, when even a short course of estradiol is combined with T treatment, the incidence of prostate cancer increases from 35% to 40% to 90% to 100% (20) . Moreover, knockout of CYP19A1 (encoding aromatase) in mice, which prevents estrogen production, elevated the circulating T levels of the mice and caused enlargement of their prostates, but this knockout did not cause the mice to develop prostate cancer (21, 22) . These observations are consistent with the conclusion that both androgen and estrogen are required for the development of prostate cancer. Furthermore, Cussenot and colleagues demonstrated the role of key estrogen metabolism-related genes, e.g., CYP1B1 and catechol-O-methyltransferase (COMT), in a large and homogeneous French cohort with prostate cancer carcinogenesis (23) . Given these important findings supporting the contribution of estrogen to prostate cancer, we sought to comprehensively determine if single-nucleotide polymorphisms (SNP) in genes associated with estradiolrelated metabolic pathways, either individually or in combination, would be predictors of prostate cancer progression. We established germline genetic signature in these pathways associated with cancer progression in localized prostate cancers and then verified these findings in locally advanced prostate cancers to evaluate the influence of the signature on overall survival.
Patients and Methods

Clinical data
The study included 739 Caucasian patients with prostate cancer divided into two independent cohorts. The first cohort was composed of 526 patients with localized prostate cancer, and the second was composed of 213 patients with locally advanced disease. Patients had undergone surgical radical prostatectomies at l'Hôtel-Dieu de Qu ebec Hospital (Qu ebec City, Canada) before being enrolled in the study. The localized and advanced prostate cancer cohorts were recruited between 1999 and 2002, and 1982 and 2002, respectively (5). The median follow-up times were 7.4 and 7.8 years for the localized and locally advanced populations, respectively. Before surgery, each participant provided written consent for genetic analysis. The local research ethics committee approved the research protocol.
Genetic analysis
DNA was extracted from peripheral blood mononuclear cells obtained at time of diagnosis. For genotyping, PCR amplification was performed on germline DNA, and the products were sequenced by Sequenom iPLEX matrixassisted laser desorption/ionization-time-of-flight mass spectrometry. The SNPs were chosen so that most of the common haplotype diversity in Caucasians would be included. A region covering the exons, introns, and 5 kb of the 5 0 and 3 0 untranslated regions immediately adjacent to each gene was screened using a haplotype-tagging SNP (htSNP) strategy to maximize coverage (5) .
Seventy-one SNPs were genotyped in localized prostate cancer and sixteen SNPs were tested in the locally advanced cases. For both populations, the average genotype call rate for all SNPs was !98%. SNPs with a missing call rate !5% were excluded. Negative controls were
Translational Relevance
Although there has been a decline in mortality rate due to early detection and better therapies, our ability to predict prostate cancer progression and metastatic behavior of a patient's cancer is still very limited. This variability in clinical outcome underscores the need to identify physiopathologic changes, in tumor cells and its microenvironment, associated with disease progression. Despite the fact that estrogens have been overshadowed by androgens in the last decades, several pieces of evidence suggested that estrogens cooperate with androgens to perpetuate carcinogenesis. We describe host genetic variations in the estradiol pathway associated with hormone levels and lethal form of prostate cancer. Single-nucleotide polymorphisms distributed across CYP1B1, HSD17B2, catechol-O-methyltransferase (COMT), and SULT2B1 were associated with progression and survival. Indeed, based on our findings, patients could be stratified into four distinct prognostic subgroups. Thus, the cumulative impact of such markers provides clinically relevant information from a single blood sample, is invariant with time, overcomes tumor heterogeneity, and identifies potential targets to optimize disease management. Our data offer a high translational potential that could lead to a personalize approach based on the presence or absence of the molecular signature and identify novel promising druggable targets.
included in each analysis, and quality controls included !5% blind duplicates.
Measurement of endogenous steroid levels
Plasma samples were collected from the localized cohort on the morning of the surgical procedure (4). We excluded patients who had received neoadjuvant hormone treatment and those with missing genotype information for the studied SNPs. Steroids were measured by validated gas chromatography-mass spectrometry or liquid chromatography-tandem mass spectrometry (4) . Deuterated steroids were added into each sample, and quality controls were included in each run. The lower quantification limits were T (0.03 ng/mL), dihydrotestosterone (DHT; 0.005 ng/mL), androsterone (ADT; 0.025 ng/mL), ADT-glucuronide (ADT-G; 1 ng/mL), 3a-diol-3G and 3a-diol-17G (0.25 ng/mL), dehydroepiandrosterone (DHEA; 0.1 ng/mL), DHEA-sulfate (DHEA-S; 0.075 mg/mL), E 1 -S (0.075 ng/ mL), estrone (E 1 ; 0.005 ng/mL), estradiol (E 2 ; 0.001 ng/ mL), androstenedione (4-dione; 0.05 ng/mL), androstenediol (5-diol; 0.05 ng/mL). Coefficients of variation for the intra-and interassays were 10.0%, and accuracy values (given in parentheses) were T (100.5%), DHT (103.5%), ADT (96.5%), ADT-G (99.5%), 3a-diol-3G (89.2%), 3a-diol-17G (100.2%), DHEA (96.13%), DHEA-S (99.9%), E 1 -S (100.45%), E 1 (106.9%), E 2 (103.15%), 4-dione (95.5%), and 5-diol (95.33%; ref. 4) .
Statistical analyses
To assess the association of the SNPs with time to biochemical recurrence (BCR), disease progression, and death, each htSNP was first categorized with the common genomic model because the function of most of these htSNPs was unknown. Minor-allele homozygotes with a frequency of <2% were grouped with the heterozygotes. A sample size of 526 patients provided a power of at least 80% to detect a HR of !1.75 for genetic variant with a frequency of 25%. Cox regression was performed for the frequency of occurrence of each SNP, with adjustments made for clinicopathologic variables. After performing a Cox regression using the genomic model, the associations of SNPs with clinical outcomes were also evaluated for genomic modes of transmission (dominant and recessive). In dominant model, for a SNP with a major allele "A" and a minor allele "b," the collective genotypes ("Ab" þ "bb") are compared with reference genotype "AA." For recessive model, "bb" is compared with collective ("AA" þ "Ab") reference group. HR of reference genotype group is arbitrary fixed at 1.00. All covariables were categorized as shown in Table 1 , and 4% of the covariables were missing. For localized prostate cancer cases, the censoring variable was time to BCR, based on a prostate-specific antigen (PSA) cut-off value !0.3 mg/L (4). For locally advanced cases, disease progression was defined as resistance to androgen-deprivation therapy, metastasis, and/or death (5). Multivariate models included PSA at diagnosis, Gleason score, pathologic tumor stage, age at diagnosis, neoadjuvant therapy, smoking status, adjuvant therapy, surgical margins, and nodal invasion status.
Kaplan-Meier analyses, log-rank tests, and univariate Cox regression analyses were also carried out for each variant. P values were considered significant if <0.05. False discovery rates (q values) were calculated to determine the degree to which the tests were prone to false positives, using the R QVALUE package (http://genomics.princeton.edu/storeylab/qvalue/).
To adjust for differences in the absolute levels of sex steroids, we calculated the residuals of the natural logarithm of each hormone level regressed on age at blood donation and smoking status. The associations with SNPs were performed by regression of the hormone residuals for each SNP using two categories: recessive and dominant with one degree of freedom. We considered the association of an SNP with the variation in hormone levels to be significant if the P value was <0.05. To facilitate the comparison between groups, we displayed the hormone level as untransformed data using the geometric mean and the SEM. Statistical analyses were performed using SAS Statistical Software version 9.2 (SAS Institute) and PASW statistics version 17 (SPSS Inc.).
Results
Experimental approach
Seventy-one htSNPs distributed in the selected genes encoding proteins involved in estrogen metabolism, namely genes encoding cytochrome P450s (CYP1B1, CYP3A4, CYP3A5, and CYP3A43), COMT, quinone reductases (NQO1 and NQO2), and sulfotransferases (SULT2A1 and SULT2B1), were studied in 526 Caucasians with localized prostate cancer in relation to time to BCR. We subsequently studied 16 markers in the advanced cohort (213 cases) to further evaluate their potential relationships to prostate cancer progression and survival. There was no evidence for deviation from Hardy-Weinberg equilibrium for the studied SNPs (n ¼ 71).
Genetic analyses of localized prostate cancer
The relative frequencies of the SNPs in patients with cancer and their corresponding HRs (95% confidence intervals, CI) are shown in Table 2 and Supplementary Tables  S1-S5 . After making adjustments for known clinicopathologic variables, ten SNPs, three in COMT, two in SULT2B1, one in CYP1B1 and NQO1, and three in NQO2 were found to be significantly associated with time to BCR. Of note, a significant association was observed for the CYP1B1 variant rs1800440 involved in the initial carcinogenic step related to 4-hydroxy catechol estrogen (CE) biosynthesis (HR, 1.64; 95% CI, 1.10-2.46; P ¼ 0.016; q ¼ 0.12). The three SNPs in the COMT variants (rs11705619; rs165849; rs9332377), encoding COMT involved in CE inactivation in the prostate, were associated with time to BCR. One additional COMT variant (rs16982844) was associated with a trend toward a greater risk of progression (HR, 1.73; 95% CI, 0.98-3.06; P ¼ 0.06). The SULT2B1 variants rs1246053 and rs2665582 were associated with BCR (HR, 1.99; 95% CI, 1.13-3.49; P ¼ 0.017; q ¼ 0.58 and HR, 0.50; 95% CI, 0.26-0.96; P ¼ 0.037; q ¼ 0.17, respectively). NQO1 rs2917670 was associated with a lower risk of progression (HR, 0.53; 95% CI, 0.29-0.97; P ¼ 0.039; q ¼ 0.58), whereas NQO2 variants were associated with an increased risk of BCR (Table 2 and  Supplementary Table S5 ). Indeed, NQO2 rs10223369, rs1143684, and rs6920900 were associated with a higher risk of progression (HR, 1.80; 95% CI, 1.24-2.60; P ¼ 0.002; q ¼ 0.06; HR, 1.51; 95% CI, 1.04-2.19; P ¼ 0.03; q ¼ 0.17; and HR, 1.89; 95% CI, 1.19-3.00; P ¼ 0.007; q ¼ 0.10, respectively).
Genetic analyses in locally advanced cases
Four of the 16 SNPs were also found in the genes of patients with advanced prostate cancer (Tables 3 and 4 and  Supplementary Tables S6 and S7 ). CYP1B1 rs1800440 was associated with progression-free survival and mortality (HR, 2.58; 95% CI, 1.47-4.52; P ¼ 0.0009; q ¼ 0.004 and HR, 3.25; 95% CI, 1.58-6.70; P ¼ 0.001; q ¼ 0.018, respectively). The COMT rs16982844 was significantly associated with an increased risk of progressive disease (HR, 3.40; 95% CI, 1.63-7.10; P ¼ 0.001; q ¼ 0.004) and death (HR, 3.86; 95% CI, 1.61-9.29; P ¼ 0.003; q ¼ 0.027). Moreover, SULT2B1 rs12460535, rs2665582, and rs10426628 were significantly associated with certain patient outcomes as follows: SULT2B1 rs10426628 and rs2665582 were associated with a lower risk of progression (HR, 0.49; 95% CI, 0.26-0.91; P ¼ 0.025; q ¼ 0.056 and HR, 0.38; 95% CI, 0.13-1.09; P ¼ 0.07; q ¼ 0.14, respectively; Table 3 ), whereas SULT2B1 rs12460535 was associated with progression (HR, 2.44; 95% CI, 1.10-5.41; P ¼ 0.028; q ¼ 0.43).
Cumulative association of adverse genotypes
We postulated that the association of the markers with prostate cancer progression might be stronger if the SNPs The major allele is to the left of the > sign and the minor allele is to the right. The numbers of minor-allele homozygotes, heterozygotes, and major-allele homozygotes are presented left to right. Table 3 . The numbers of minor-allele homozygotes, heterozygotes, and major-allele homozygotes are presented left to right.
c Cox regression models included PSA at diagnosis, Gleason score, pathologic T stage, age at diagnosis, neoadjuvant hormone therapy, smoking status, adjuvant therapy, surgical margin, and nodal invasion status. The major-allele homozygotes served as the reference group with a fixed HR of 1.00. When minor-allele homozygotes were rarely found (frequency 2%), they were combined with the heterozygotes; therefore, only the dominant/recessive model is shown (genomic model is empty). The major allele is to the left of the > sign and the minor allele is to the right. The numbers of minor-allele homozygotes, heterozygotes, and major-allele homozygotes are presented left to right.
associated with these interconnected estrogen biotransformation pathways were assessed in combination. Because we had demonstrated a prominent role in prostate cancer progression for common genetic variants in the HSD17B2-related conversion of estradiol or estrone, we also included variants of this gene in the combinatorial analyses. Thus, the cumulative effects of the most prognostically promising SNPs (CYP1B1 rs1800440, HSD17B2 rs1364287, rs4243229, rs2955162, rs1119933, and SULT2B1 rs12460535, rs2665582, rs10426628) were assessed for significant association with prostate cancer progression and overall patient survival (Fig. 1 ). Using these eight SNPs (of which SULT2B1 rs2665582 and rs10426628 are protective), patients were stratified into four prognostic subgroups (Fig. 1) . Together, the combination of these markers had a cumulative association with PCa progression ranging from 87% (group 1) to 55% (group 4) in BCR-free survival in localized PCa (Fig. 1, panel A) and from 95% (group 1) to 9% (group 4) in PFS in locally advanced disease (Fig. 1, panel B) . Indeed, the addition of each risk allele increased the risk of progression (localized PCa: HR, 1.73; 95% CI, 1.40À2.14; p ¼ 5 10À7; locally advanced PCa: HR, 2.56; 95% CI, 1.78À3.69; p ¼ 4 10À7). Survival curves of the locally advanced cohort are shown in Fig. 1 
Relationship between prostate cancer outcomes and endogenous sex steroid hormones
We found positive associations between germline markers linked to prostate cancer outcomes and circulating endogenous sex steroid levels, although such associations were not observed for estradiol, estrone, and estrone-sulfate, the only three estrogens measured in our study. COMT rs16982844 and CYP1B1 rs1800440 were associated, respectively, with higher levels of adrenal precursors (DHEA, DHEA-S, and 5-diol) and lower levels of inactive DHT metabolites (3a-DIOL-3 and -17 glucuronides; Table  5 ). Also, the protective SULT2B1 rs10426628 allele, associated with a reduced risk of progression, was persistently associated with reduced circulating levels of many of the measured steroids and increased levels of inactive glucuronide conjugates. A similar effect was observed for the protective SNPs in SULT2B1 rs12460535 and rs2665582 (Table 5 ).
Discussion
We report herein novel inherited molecular prognostic markers for prostate cancer found in CYP1B1, SULT2B1, COMT, NQO1, and NQO2 associated with multiple estrogen-related pathways (Fig. 2) . It is well established that steroid hormones play a central role in prostate cancer progression. Indeed, the improved outcomes for patients on androgen deprivation, abiraterone acetate (24, 25) and MDV-3100 (26) therapies clearly demonstrate the Figure 1 . Association of inherited variations in CYP1B1, SULT2B1, and HSD17B2 with PCa progression. Prognostic SNPs located in CYP1B1, SULT2B1, and HSD17B2 were combined in relation to biochemical recurrence (BCR) in (A) the Caucasian cohort with localized PCa (n ¼ 526), (B) progression-free survival, and (C) overall survival in the locally advanced cohort (n ¼ 213). Log-rank (LR) p values are shown in each frame. Table 5 . Association between positive markers in CYP1B1, COMT and SULT2B1, and endogenous steroid hormones levels. The major allele is to the left of the > sign and the minor allele is to the right. Total steroid levels (geometric mean AE SEM).
c P values from linear regression of the natural logarithm of each hormone level regressed on age at blood donation and smoking status on the SNP under each model.
importance of androgens in prostate cancer progression at all disease stages. Previous studies have suggested that, in addition to androgens, estrogens may contribute to prostate cancer development and progression (18, 19, 23, 27) . Studies performed with humans and rodents suggested that estrogens and their metabolites could be drivers of carcinogenesis (18, 28) . Furthermore, CYP1B1 and COMT are associated with prostate cancer risk (23), highlighting the significance of these genes in prostate cancer carcinogenesis. To our knowledge, however, a comprehensive assessment of the genes related to estrogen pathways has not been made in relation to a prognostic point of view. We thus evaluated the impact of single and cumulative adverse and protective genetic markers associated with prostate cancer progression. This study demonstrates that germline polymorphisms in genes associated with estrogen and CE metabolic pathways are associated with prostate cancer progression in Caucasians with localized and locally advanced disease. Remarkably, positive findings were observed for both cohorts for variants of CYP1B1, SULT2B1, and COMT, which suggests a role for these genes in prostate cancer progression. The cumulative association of the polymorphisms found for these genes also suggests that E 2 , its metabolites, and/or their repercussion on the androgen axis are potentially involved in prostate cancer progression. In addition, their roles in regulating the concentration of E 2 and other biologically active metabolites, such as CYP1B1 involved in the production of 4-hydroxy-metabolites of E 2 and E 1 , may result in the generation of large amounts of reactive oxygen species (17) , which may cause DNA damage and thereby enhance prostate carcinogenesis and progression. Indeed, several studies have demonstrated the role of certain estrogen metabolites, e.g., CE, in DNA-adduct formation and carcinogenicity (28) . Such mutagenic compounds include mostly 4-hydroxy-metabolites of estrogens, which can be further oxidized to CE quinones. In contrast, COMT, SULT2B1, and NQO1/2 reduce the accumulation of reactive oxygen species (28) and are involved in the formation of protective or less reactive metabolites; therefore, these genes may be involved in host defence (Fig. 2) .
CYP1B1 rs1800440 has the amino acid replacement Asn ! Ser at position 453, which subjects it to proteasomal degradation in a recombinant system (17, 29) . This variant is associated with lower levels of 2-hydroxy and 16a-hydroxy estrogens in women with a family history of breast cancer, thus revealing its role in estrogen biotransformation in humans (30) . Moreover, CYP1B1 is overexpressed in prostate cancer and may, in addition to its role in estrogen biotransformation, also catalyze 6-hydroxylation of T, and therefore this gene would have a dual role in the sex steroid hormonal pathway. This function of CYP1B1 reflects changes observed in androgen glucuronide levels in association with rs1800440 ( Table 5 ). The complex role of the CYP1B1 enzyme in androgen and estrogen metabolism, combined with its role in prostate cancer risk and progression, definitely warrants additional investigation. Interestingly, NQO1 and NQO2 SNPs are associated with progression only in localized prostate cancer, suggesting a potential role for this pathway early in the course of disease. Possibly, the combination of polymorphisms in these estrogen-related genes modifies sex steroid exposure, e.g., estrogen and CE exposure, or their relative abundance (compared with androgens) and thereby favors cancer progression. This postulate remains to be demonstrated. Moreover, the known association of HSD17B2 with cancer progression (5, 31) may also be related to its ability to catalyze the conversion of CE metabolites in addition to its role in converting E 2 to E 1 (Fig. 2) .
Given the interrelationship among these pathways, we assessed the cumulative effect of variations in the related genes on prostate cancer progression to establish if a combination of markers would be more predictive than individual SNPs. As hypothesized, although the presence of each SNP is modestly informative, their cumulative association is more predictive of outcome. Remarkably, the cumulative association of these SNPs with the HSD17B2 markers stratifies these patients into four prognostic subgroups (Fig. 1) . The most promising eight-marker signature [CYP1B1, (rs1800440), SULT2B1 Figure 2 . The estrogen and catechol estrogen biosynthetic pathways. 17bHSD, 17b-hydroxysteroid dehydrogenase; 17bHSD2, 17b-hydroxysteroid dehydrogenase type 2; CYP1B1, cytochrome P450 1B1; SULT2B1, sulfotransferase 2B1; 4-OHE1, 4-hydroxy-estrone; 4-OHE2, 4-hydroxy-estradiol; 2-OHE1, 2-hydroxy-estrone; 2-OHE2, 2-hydroxy-estradiol; 2-MeOHE1, 2-methoxy-estrone; 2-MeOHE2, 2-methoxy-estradiol; 4-MeOHE1, 4-methoxy-estrone; 4-MeOHE2, 4-methoxy-estradiol; E1, estrone; E2, estradiol; Q, quinone; CYP1A1, cytochrome P450 1A1; NQO1, NAD (P) H dehydrogenase, quinone 1; NQO2, NAD (P) H dehydrogenase, quinone 2.
(rs12460535, rs2665582, rs10426628), and HSD17B2 (rs4243229, rs1364287, rs2955162, rs1119933)] has a cumulative association with PCa progression in localized and in locally advanced disease. Indeed, the BCR-free and progression-free survival stratifications are respectively 87%, 80%, 72%, and 55% in localized and 95%, 87%, 73%, and 9% in locally advanced diseases (Fig. 1) .
In support of their role(s) in cancer progression and the plausibility of our hypothesis, it is notable that these germline variations are associated with alterations in circulating hormone levels, which may create a specific environment needed for cell population expansion. Of importance is the relationship observed for the SULT2B1 htSNPs and several circulating steroids. The protective SNP rs10426628, located in intron 3 of SULT2B1, is associated with lower levels of systemic T, DHT, and androsterone and higher levels of glucuronides, illustrating the broad effect on hormonal exposure associated with this SNP. Therefore, in addition to its potential role on CE inactivation, this SULT2B1 variant seems to affect events upstream of the steroidogenesis of cholesterol, DHEA, and sulfatation of pregnenolone, thereby controlling steroid bioavailability of sex steroid precursors.
To improve our understanding of the steroidogenic pathways in patients with prostate cancer, it will be crucial to integrate the levels and ratios of circulating androgens, estrogens, and their metabolites in individuals with a normal prostate and patients with prostate cancer to completely evaluate the hormonal milieu associated with disease aggressiveness and progression. Overall, the presence of such variations in the steroidogenic pathway may have a major consequence(s) on fine paracrine and intracrine regulation of key steroid carcinogenic drivers. The role of estrogens and their derivatives definitely deserves more attention because they can have diverse effects on progression such as (i) several 4-hydroxy-CE metabolites can still bind the estrogen receptor with very high affinity, the latter also being positively associated with prostate cancer progression (4), (ii) 4-hydroxy-CE metabolites can increase DNA-adduct formation as reported for several other cancers (28) , creating a favorable environment for additional genomic mutagenesis and proliferation, and (iii) MeOHEs can contribute to the prevention of cancer progression given their antiproliferative, proapoptotic, and antiangiogenic functions.
The strengths of our study include the large number of patients, a candidate gene approach related to a specific steroidogenic pathway, the substantial plausibility of an association(s) based on the biologic functions of the selected genes, expression of their corresponding enzymes in the human prostate, repeated associations in the two independent and different types of cohorts, a significant follow-time (!7 years), associations between circulating steroid levels and progression-free, and overall survival endpoints.
Limitations of the study are related to the absence of data about circulating estrogen derivatives and the smaller cohort of patients with advanced disease. On the basis of our results (4, 5, 32) and those of others (8, 33, 34) , it is expected that the most promising individual germline variants associated with outcomes will have OR/HR values around 2.0. In our study, two markers (rs16982844 and rs1800440) are above this threshold. Interestingly, these two SNPs are also associated with significant changes in circulating steroid hormone levels, which clearly reinforce their role in disease progression. However, these stronger associations observed in the advanced cohort might overestimate the magnitude of the effect compared with results obtained in localized disease, especially due to smaller size of the cohort and to the fact that our endpoints in this population included not only death but also androgen-deprivation therapy and metastasis. Thus, before clinical translation, our findings require further validation in larger, independent, and interethnic prostate cancer cohorts.
In conclusion, the cumulative association of inherited molecular markers in the estrogenic pathways is certain to become attractive prognostic markers for prostate cancer progression. Indeed, the cumulative impact of such markers provides clinically relevant information from a single blood sample, which requires only a simple methodology, is invariant with time, overcomes tumor heterogeneity, and may identify potential targets for a more personalized approach. The impact of such host markers will help us understand genetic factors associated with hormone levels in the microenvironment of prostate cancer cells, which may promote paracrine-dependent tumor propagation. It will be critical to determine the influence of these markers on intracrine steroid conversion, which undeniably also supports cell proliferation. In addition to previous findings about prostate cancer risk, variations in estrogen-related genes such as ESR1, HSD17B2, CYP1B1, SULT2B1, and COMT point toward a polygenic contribution of estrogen-related genes with prostate cancer progression. The cumulative association of CYP1B1 (rs1800440), SULT2B1 (rs12460535, rs2665582, and rs10426628) with HSD17B2 (rs4243229, rs1364287, rs2955162, and rs1119933) may help stratify patients into four distinct subgroups for the purpose of establishing an appropriate prognosis. Overall, it is expected that combinations of markers in steroidogenic pathways, rather than SNP considered individually, will be more valuable at predicting outcomes. Our findings may ultimately lead to an improved understanding of host-tumor/hormonal interactions underlying cancer progression and certainly constitute an additional step toward a more personalized approach to prostate cancer management.
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